AMP-activated protein kinase suppresses the in vitro and in vivo proliferation of hepatocellular carcinoma

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Cheng, Jidong ^a   Huang, Tianliang ^a   Li, Youfeng ^a   Guo, Yubai ^a   Zhu, Yuzhang ^a   Wang, Qingjia ^a   Tan, Xiaojun ^a   Chen, Weisheng ^a   Zhang, Yongneng ^a   Cheng, Weijie ^a   Yamamoto, Tetsuya ^b   Jing, Xubin ^a   Huang, Jiexiong ^a  

^a SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; KI 67 ANTIGEN; METFORMIN; 5 AMINO 4 IMIDAZOLECARBOXAMIDE; AICA RIBONUCLEOTIDE; ANTIDIABETIC AGENT; RIBONUCLEOTIDE; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER INHIBITION; CAPILLARY DENSITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR BLEEDING; TUMOR NECROSIS; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; ENZYMOLOGY; HEPG2 CELL LINE; LIVER TUMOR; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; XENOGRAFT;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; HEP G2 CELLS; HETEROGRAFTS; HUMANS; HYPOGLYCEMIC AGENTS; KI-67 ANTIGEN; LIVER NEOPLASMS; METFORMIN; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RIBONUCLEOTIDES;

EID: 84899408432     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0093256     Document Type: Article

References (35)

1. Hardie DG (2007) AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785.
2. Hardie DG, Hawley SA, Scott JW (2006) AMP-activated protein kinase-development of the energy sensor concept. J Physiol 574: 7-15. (Pubitemid 43905792)
3. Tamas P, Hawley SA, Clarke RG, Mustard KJ, Green K, et al. (2006) Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca2+ in T lymphocytes. J Exp Med 203: 1665-1670. (Pubitemid 44036271)
4. Horman S, Browne G, Krause U, Patel J, Vertommen D, et al. (2002) Activation of AMP-activated protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. Curr Biol 12: 1419-1423. (Pubitemid 34915545)
5. Carling D, Zammit VA, Hardie DG (1987) A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 223: 217-222.
6. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N (2007) Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812. (Pubitemid 350145909)
7. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, et al. (2002) Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659-3662. (Pubitemid 34728843)
8. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun 321: 161-167. (Pubitemid 39055618)
9. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305. (Pubitemid 40813563)
10. Giardiello FM, Welsh SB, Hamilton SR, Offerhaus GJ, Gittelsohn AM, et al. (1987) Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 316: 1511-1514. (Pubitemid 17076235)
11. Nakau M, Miyoshi H, Seldin MF, Imamura M, Oshima M, et al. (2002) Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice. Cancer Res 62: 4549-4553.
12. Wang W, Guan KL (2009) AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 196: 55-63.
13. Siegel AB, Zhu AX (2009) Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 115: 5651-5661.
14. Schutte K, Bornschein J, Malfertheiner P (2009) Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 27: 80-92.
15. Wood WJ, Rawlings M, Evans H, Lim CN (1988) Hepatocellular carcinoma: importance of histologic classification as a prognostic factor. Am J Surg 155: 663-666.
16. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, et al. (1996) New Inuyama classification; new criteria for histological assessment of chronic hepatitis∧ 1. International hepatology communications 6: 112-119. (Pubitemid 27059904)
17. Koomagi R, Volm M (1999) Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 84: 239-243. (Pubitemid 29256748)
18. Hardie DG (2004) The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 117: 5479-5487.
19. Hardie DG (2003) Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144: 5179-5183.
20. Kyriakis JM (2003) At the crossroads: AMP-activated kinase and the LKB1 tumor suppressor link cell proliferation to metabolic regulation. J Biol 2: 26.
21. Luo Z, Saha AK, Xiang X, Ruderman NB (2005) AMPK, the metabolic syndrome and cancer. Trends Pharmacol Sci 26: 69-76. (Pubitemid 40170168)
22. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598-608.
23. Garber K (2006) Energy deregulation: licensing tumors to grow. Science 312: 1158-1159.
24. Kahn BB, Alquier T, Carling D, Hardie DG (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1: 15-25. (Pubitemid 43960587)
25. Qu Z, Zhang Y, Liao M, Chen Y, Zhao J, et al. (2012) In vitro and in vivo antitumoral action of metformin on hepatocellular carcinoma. Hepatol Res 42 :922-33.
26. Chen HP, Shieh JJ, Chang CC, Chen TT, Lin JT, et al. (2013) Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut 62:606-15.
27. Rattan R, Giri S, Singh AK, Singh I (2005) 5-Aminoimidazole-4- carboxamide-1-beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J Biol Chem 280: 39582-39593. (Pubitemid 41713917)
28. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, et al. (2006) Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 12: 3209-3215. (Pubitemid 43837371)
29. Tiainen M, Ylikorkala A, Makela TP (1999) Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A 96: 9248-9251. (Pubitemid 29374740)
30. Short JD, Dere R, Houston KD, Cai SL, Kim J, et al. (2010) AMPK-mediated phosphorylation of murine p27 at T197 promotes binding of 14-3-3 proteins and increases p27 stability. Mol Carcinog 49: 429-439.
31. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, et al. (2005) AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293. (Pubitemid 41350534)
32. Imamura K, Ogura T, Kishimoto A, Kaminishi M, Esumi H (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 287: 562-567. (Pubitemid 32917636)
33. Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, et al. (2007) The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol 9: 218-224. (Pubitemid 46420865)
34. Nam M, Lee WH, Bae EJ, Kim SG (2008) Compound C inhibits clonal expansion of preadipocytes by increasing p21 level irrespectively of AMPK inhibition. Arch Biochem Biophys 479: 74-81.
35. Rahman MA, Dhar DK, Yamaguchi E, Maruyama S, Sato T, et al. (2001) Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res 7: 1325-1332. (Pubitemid 32708688)